Literature DB >> 15173327

GLP-1: target for a new class of antidiabetic agents?

C Mark B Edwards1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15173327      PMCID： PMC1079489          DOI： 10.1177/014107680409700604

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  70 in total

1.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Authors:  C M Edwards; J F Todd; M Mahmoudi; Z Wang; R M Wang; M A Ghatei; S R Bloom
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

2.  Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

Authors:  J F Todd; C M Edwards; M A Ghatei; H M Mather; S R Bloom
Journal:  Clin Sci (Lond)       Date:  1998-09       Impact factor: 6.124

3.  Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.

Authors:  D M Nathan; E Schreiber; H Fogel; S Mojsov; J F Habener
Journal:  Diabetes Care       Date:  1992-02       Impact factor: 19.112

4.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

Authors:  R Mentlein; B Gallwitz; W E Schmidt
Journal:  Eur J Biochem       Date:  1993-06-15

5.  Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.

Authors:  B Thorens; A Porret; L Bühler; S P Deng; P Morel; C Widmann
Journal:  Diabetes       Date:  1993-11       Impact factor: 9.461

6.  Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.

Authors:  C M Edwards; J F Todd; M A Ghatei; S R Bloom
Journal:  Clin Sci (Lond)       Date:  1998-12       Impact factor: 6.124

7.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

Authors:  M A Nauck; E Bartels; C Orskov; R Ebert; W Creutzfeldt
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

8.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

Authors:  M Gutniak; C Orskov; J J Holst; B Ahrén; S Efendic
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Authors:  M A Nauck; M M Heimesaat; C Orskov; J J Holst; R Ebert; W Creutzfeldt
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808
View more
  3 in total

1.  The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line.

Authors:  A Gameiro; F Reimann; A M Habib; D O'Malley; L Williams; A K Simpson; F M Gribble
Journal:  J Physiol       Date:  2005-10-13       Impact factor: 5.182

2.  Insulin secretion induced by glucose-dependent insulinotropic polypeptide requires phosphatidylinositol 3-kinase γ in rodent and human β-cells.

Authors:  Jelena Kolic; Aliya F Spigelman; Alannah M Smith; Jocelyn E Manning Fox; Patrick E MacDonald
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

Review 3.  Nutritional regulation of glucagon-like peptide-1 secretion.

Authors:  Gwen Tolhurst; Frank Reimann; Fiona M Gribble
Journal:  J Physiol       Date:  2008-11-10       Impact factor: 5.182
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.